Drugs Made in America Acquisition II Corp. filed a Form 8-K on November 18, 2026, disclosing a preliminary business combination proposal delivered to Alpha AI Biotech Group on October 29, 2026, alongside the consolidation of $700,000 in convertible notes financing.

Key Highlights

  • Preliminary proposal: The company delivered a proposal to Alpha AI Biotech Group on October 29, 2026, contemplating a pre-money equity valuation of Alpha of $600 million, payable in 60,000,000 ordinary shares at $10.00 per share.
  • Earn-out shares: Alpha shareholders could receive up to 30,000,000 additional ordinary shares in two equal tranches, subject to share-price thresholds of $12.50 and $15.00 during the 24 months after closing.
  • Standstill approved: The company's Board of Directors approved a limited 30-day standstill on November 3, 2026, expiring on or about December 3, 2026, that restricts only the consummation of a competing transaction.
  • Consolidated Note: Three prior funding installments totaling $700,000 will be consolidated into a single convertible promissory note maturing June 30, 2027, replacing notes that would otherwise have matured in December 2026.
  • Conversion discount: The Consolidated Note may, at the Investor's option upon completion of a business combination, be converted at a 35% discount to the market price of shares at the time of conversion.
  • Remaining commitment: Following the November 6, 2026 installment of $250,000, $700,000 of the total $1,400,000 Convertible Notes Financing remains available under the Agreement.
  • Conflict of interest noted: Alon Izidor Tal, CEO of the Investor, is also a director of Alpha and acknowledged the Proposal on Alpha's behalf; the company's Board, consisting entirely of independent directors, was aware of these relationships.

DMII Outlines Alpha AI Biotech Combination Terms and Consolidates Convertible Notes

According to the filing, Drugs Made in America Acquisition II Corp. (NASDAQ:DMIIU, NASDAQ:DMII, NASDAQ:DMIIR) delivered a preliminary proposal to Alpha AI Biotech Group on October 29, 2026. Alpha acknowledged and accepted the Proposal in principle on October 30, 2026. The Proposal contemplates a pre-money equity valuation of $600 million for Alpha, with consideration structured as 60,000,000 ordinary shares of the company at $10.00 per share. The filing states that the Proposal is a nonbinding expression of interest, except for its confidentiality provisions, the limited standstill, and a funding acknowledgment.

The filing discloses that the Board approved a 30-day standstill on November 3, 2026, which the filing describes as restricting "only the consummation of a competing transaction" and explicitly states it "does not prevent either party from evaluating or negotiating alternatives." The filing notes that "the Board's approval of the standstill does not constitute approval of any business combination." The Proposal remains subject to satisfactory due diligence, audited financial statements, execution of definitive agreements, and required board, shareholder, and regulatory approvals, according to the filing.

Separately, the filing discloses the creation of a direct financial obligation. The company and its Investor, Tal Alpha Yezum Vekidum Asakim (2003) Ltd., agreed to consolidate an existing Bridge Note of $150,000, a Second Note of $300,000, and the new $250,000 installment funded on November 6, 2026, into a single Consolidated Note with a principal amount of $700,000, maturing June 30, 2027. The filing reports that $700,000 of the total $1,400,000 Convertible Notes Financing remains available under the Agreement, and states that the Investor's funding commitment is not contingent on approval or closing of the proposed transaction with Alpha.

What Was Disclosed

The Form 8-K discloses a nonbinding preliminary proposal for a potential business combination with Alpha AI Biotech Group at a $600 million pre-money valuation, a related 30-day standstill, the consolidation of $700,000 in convertible notes into a single note maturing June 30, 2027, and a noted conflict of interest involving Alon Izidor Tal.